794.8500 12.05 (1.54%)
NSE Oct 29, 2026 15:31 PM
Volume: 63,490
 

Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 777.8
More from Alembic Pharmaceuticals Ltd.
Recommended